期刊
PHARMACOGENOMICS
卷 16, 期 11, 页码 1275-1284出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs.15.70
关键词
capecitabine; dihydropyrimidine dehydrogenase; DPYD; 5-fluorouracil; fluoropyrimidines; gene activity score; individualized medicine; pharmacogenomics
资金
- Dutch Cancer Society
- Roche Pharmaceuticals
The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in the metabolism of fluoropyrimidines. DPD deficiency occurs in 4-5% of the population and is associated with severe fluoropyrimidine-related toxicity. Several SNPs in DPYD have been described that lead to absent or reduced enzyme activity, including DPYD*2A, DPYD*13, c.2846A>T and c.1236G>A/haplotype B3. Since these SNPs differ in their effect on DPD enzyme activity, a differentiated dose adaption is recommended. We propose the gene activity score for translating DPYD genotype into phenotype, accounting for differences in functionality of SNPs. This method can be used to standardize individualized fluoropyrimidine dose adjustments, resulting in optimal safety and effectiveness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据